KYNB

Kyntra Bio, Inc. is a biotechnology company developing novel treatments for inflammatory bowel disease (IBD) and other inflammatory conditions. The company's lead programs focus on developing selective antibodies that target specific pathways involved in chronic inflammation. Kyntra's therapeutic candidates aim to provide more targeted and effective treatments for patients with Crohn's disease, ulcerative colitis, and related autoimmune disorders.